We are thrilled to announce that Dr. Erez Eitan, NeuroDex’s chief scientific officer (CSO), will participate in the upcoming Alzheimer’s Association International Conference (AAIC) 2024. This prestigious event, taking place from July 28 to August 1 in Philadelphia, USA, will bring together leading scientists, researchers, and healthcare professionals from around the globe to discuss the…
Imagine a future where the onset of Alzheimer’s or Parkinson’s disease could be predicted and effectively treated before symptoms even appear. Neurodegenerative diseases have long remained shrouded in a veil of uncertainty, with definitive diagnoses often coming too late to alter their devastating trajectories. Biomarkers are the beacons of hope in this landscape, potentially revolutionizing…
Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…
Introduction: The global Neurodegenerative Disease Market is on the cusp of significant expansion, driven by the rising prevalence of neurodegenerative diseases such as Parkinson’s, multiple sclerosis, and Alzheimer’s disease. According to a recent study by MarketDigits, the market is projected to reach USD 69.8 billion by 2030, growing at a robust CAGR of 6.2% during…
Introduction Leqembi® Arrives in China for Alzheimer’s Care Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare. Understanding Alzheimer’s and…
Introduction Once thought to be mere cellular debris, exosomes have emerged as significant players in neurodegenerative diseases. These extracellular vesicles, ranging from 30 to 100 nm in size, are produced by all cell types in the central nervous system (CNS). Far from being simple waste disposal units, exosomes are involved in complex intercellular communication and…
Athira Pharma, Inc. (NASDAQ: ATHA), a leading late-stage biopharmaceutical company dedicated to pioneering small molecules that rejuvenate neurons and decelerate neurodegeneration, has unveiled compelling findings from its SHAPE Phase 2 clinical trial. This trial assessed the potential of fosgonimeton (ATH-1017) in patients grappling with Parkinson’s disease, dementia, and dementia with Lewy bodies. Fosgonimeton Fosgonimeton is a…
In a remarkable stride towards advancing healthcare, Canadian innovators have unveiled a groundbreaking artificial intelligence (AI) program to transform the early detection of Amyotrophic Lateral Sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA) takes immense pride in supporting this revolutionary AI technology, which harnesses the power of AI to scrutinize de-identified electronic medical records (EMRs). This…
Cambridge, MA & Singapore, August 09, 2023 Sunbird Bio, a pioneering biotechnology company focused on advancing the diagnosis and treatment of neurological disorders and early-stage cancer through proprietary protein-based technologies, has successfully merged with Glympse Bio. The merger aims to expedite the development of the two companies protein-based diagnostic platforms, creating a powerful entity named…
Introduction Eli Lilly recently presented the full results from their Phase 3 TRAILBLAZER-ALZ 2 study at the Alzheimer’s Association International Conference (AAIC). The study focused on evaluating the effectiveness of donanemab, a potential treatment for early symptomatic Alzheimer’s disease (AD). The results, also published in the Journal of the American Medical Association (JAMA), demonstrated that…